Last reviewed · How we verify

89Zr-DFO-girentuximab — Competitive Intelligence Brief

89Zr-DFO-girentuximab (89Zr-DFO-girentuximab) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Monoclonal antibody-drug conjugate. Area: Oncology.

phase 1 Monoclonal antibody-drug conjugate CD22 Oncology Small molecule Live · refreshed every 30 min

Target snapshot

89Zr-DFO-girentuximab (89Zr-DFO-girentuximab) — NYU Langone Health. Targeting CD22

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
89Zr-DFO-girentuximab TARGET 89Zr-DFO-girentuximab NYU Langone Health phase 1 Monoclonal antibody-drug conjugate CD22
Lumoxiti MOXETUMOMAB PASUDOTOX AstraZeneca marketed B-cell receptor CD22 2018-01-01
INOTUZUMAB OZOGAMICIN INOTUZUMAB OZOGAMICIN marketed CD22-directed Immunoconjugate [EPC] CD22 2017-01-01
Besponsa inotuzumab-ozogamicin Pfizer marketed Antibody-drug conjugate (ADC) CD22 2017-01-01
Besponsa inotuzumab Pfizer marketed CD22-directed Immunoconjugate [EPC] CD22 2017-01-01
Inotuzumab ozogamicin (INO) Inotuzumab ozogamicin (INO) Charite University, Berlin, Germany marketed Antibody-drug conjugate (ADC) CD22
Besponsa Inotuzumab Ozogamicin Pfizer Inc. marketed Antibody-drug conjugate (ADC) CD22

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Monoclonal antibody-drug conjugate class)

  1. GlaxoSmithKline · 2 drugs in this class
  2. RemeGen Co., Ltd. · 2 drugs in this class
  3. Copharos · 1 drug in this class
  4. Eastern Cooperative Oncology Group · 1 drug in this class
  5. Merck Sharp & Dohme LLC · 1 drug in this class
  6. Mirati Therapeutics Inc. · 1 drug in this class
  7. NYU Langone Health · 1 drug in this class
  8. The Lymphoma Academic Research Organisation · 1 drug in this class
  9. Astellas Pharma Global Development, Inc. · 1 drug in this class
  10. Yan Zhang, MD · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). 89Zr-DFO-girentuximab — Competitive Intelligence Brief. https://druglandscape.com/ci/89zr-dfo-girentuximab. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: